Citations

Showing 10 of 108081 citations.

Sleep Disturbances in Cervical Spondylotic Myelopathy
Bisson, Erica F. , Mummaneni, Praveen V. , Michalopoulos, Giorgos D. , Chan, Andrew K. , Agarwal, Nitin , Wang, Michael Y. , Knightly, John J. , Sherrod, Brandon A. , Gottfried, Oren N., Than, Khoi D. , Shaffrey, Christopher I. , Virk, Michael S. , Hussain, Ibrahim , Shabani, Saman , Glassman, Steven D. , Tumialan, Louis M., Turner, Jay D. , Uribe, Juan S. , Meyer, Scott A., Lu, Daniel C. , Buchholz, Avery L., Upadhyaya, Cheerag D., Shaffrey, Mark E., Park, Paul , Foley, Kevin T. , Coric, Domagoj , Slotkin, Jonathan R., Potts, Eric A. , Stroink, Ann R., Chou, Dean , Fu, Kai-Ming, Haid, Regis W., Asher, Anthony L. , Bydon, Mohamad , Uribe, Juan S. , El Sammak, Sally, Michalopoulos, Giorgos , Sammak, Sally El , Goldberg, Jacob L.

Mayo Clinic

Clinical Spine Surgery | March 15, 2023 | Volume: 36 | Issue: 3 | Pages: 112-119

10.1097/bsd.0000000000001454 | PMID 36920372 Get It

Study Design: Prospective observational study, level of evidence 1 for prognostic investigations. Objectives: To evaluate the prevalence of sleep impairment and predictors of improved sleep quality 24 months postoperatively in cervical spondylotic myelopathy (CSM) using the quality outcomes database. Summary of Background Data: Sleep disturbances are a common yet understudied symptom in CSM. Materials and Methods: The quality outcomes database was queried for patients with CSM, and sleep quality was assessed through the neck disability index sleep component at baseline and 24 months postoperatively. Multivariable logistic regressions were performed to identify risk factors of failure to improve sleep impairment and symptoms causing lingering sleep dysfunction 24 months after surgery. Results: Among 1135 patients with CSM, 904 (79.5%) had some degree of sleep dysfunction at baseline. At 24 months postoperatively, 72.8% of the patients with baseline sleep symptoms experienced improvement, with 42.5% reporting complete resolution. Patients who did not improve were more like to be smokers [adjusted odds ratio (aOR): 1.85], have osteoarthritis (aOR: 1.72), report baseline radicular paresthesia (aOR: 1.51), and have neck pain of ≥4/10 on a numeric rating scale. Patients with improved sleep noted higher satisfaction with surgery (88.8% vs 72.9%, aOR: 1.66) independent of improvement in other functional areas. In a multivariable analysis including pain scores and several myelopathy-related symptoms, lingering sleep dysfunction at 24 months was associated with neck pain (aOR: 1.47) and upper (aOR: 1.45) and lower (aOR: 1.52) extremity paresthesias. Conclusion: The majority of patients presenting with CSM have associated sleep disturbances. Most patients experience sustained improvement after surgery, with almost half reporting complete resolution. Smoking, osteoarthritis, radicular paresthesia, and neck pain ≥4/10 numeric rating scale score are baseline risk factors of failure to improve sleep dysfunction. Improvement in sleep symptoms is a major driver of patient-reported satisfaction. Incomplete resolution of sleep impairment is likely due to neck pain and extremity paresthesia.
Is Severe Neck Pain a Contraindication to Performing Laminoplasty in Patients With Cervical Spondylotic Myelopathy?
Pinter, Zachariah W. , Mikula, Anthony L. , Reed, Ryder, Lakomkin, Nikita , Townsley, Sarah E., Wright, Breydan, Kazarian, Erick R., Michalopoulos, Giorgos D. , Currier, Bradford L. , Freedman, Brett A. , Bydon, Mohamad , Elder, Benjamin D. , Fogelson, Jeremy L. , Sebastian, Arjun S. , Fogelson, Jeremy, Michalopoulos, Giorgos , Nassr, Ahmad

Mayo Clinic

Clinical Spine Surgery | March 15, 2023 | Volume: 36 | Issue: 3 | Pages: 127-133

10.1097/bsd.0000000000001444 | PMID 36920406 Get It

Study Design: Retrospective review. Objective: The purpose of this study was to investigate the surgical outcomes in a cohort of patients with severe preoperative axial neck pain undergoing laminoplasty for cervical spondylotic myelopathy (CSM). Summary of Background Data: No study has investigated whether patients with severe axial symptoms may achieve satisfactory neck pain and disability outcomes after laminoplasty. Methods: We performed a retrospective review of 91 patients undergoing C4-6 laminoplasty for CSM at a single academic institution between 2010 and 2021. Patient-reported outcome measures (PROMs), including Neck Disability Index (NDI), visual analog scale (VAS) Neck, and VAS Arm, were recorded preoperatively and at 6 months and 1 year postoperatively. Patients were stratified as having mild pain if VAS neck was 0–3, moderate pain if 4–6, and severe pain if 7–10. PROMs were then compared between subgroups at all the perioperative time points. Results: Both the moderate and severe neck pain subgroups demonstrated a substantial improvement in VAS neck from preoperative to 6 months postoperatively (−3.1±2.2 vs. −5.6±2.8, respectively; P<0.001), and these improvements were maintained at 1 year postoperatively. There was no difference in VAS neck between subgroups at either the 6-month or 1-year postoperative time points. Despite the substantially higher mean NDI in the moderate and severe neck pain subgroups preoperatively, there was no difference in NDI at 6 months or 1 year postoperatively (P=0.99). There were no differences between subgroups in the degree of cord compression, severity of multifidus sarcopenia, sagittal alignment, or complications. Conclusions: Patients with moderate and severe preoperative neck pain undergoing laminoplasty achieved equivalent PROMs at 6 months and 1 year as patients with mild preoperative neck pain. The results of this study highlight the multifactorial nature of neck pain in these patients and indicate that severe axial symptoms are not an absolute contraindication to performing laminoplasty in well-aligned patients with CSM.
Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression
Tritz, Zachariah P. , Ayasoufi, Katayoun , Wolf, Delaney M. , Owens, Carley A. , Malo, Courtney S. , Himes, Benjamin , Fain, Cori E. , Goddery, Emma N. , Yokanovich, Lila T. , Jin, Fang , Hansen, Michael J. , Wang, Chensu , Marcano, Rosa M. Diaz , Vile, Richard G. , Johnson, Aaron J. , Himes, Benjamin T , Parney, Ian F , Wang, Chensu , Moynihan, Kelly D , Irvine, Darrell J , Wittrup, K Dane , Diaz Marcano, Rosa M , Vile, Richard G , Johnson, Aaron J. , Ayasoufi, Katayoun , Parney, Ian F.

Mayo Clinic

Cancer Immunology Research | March 15, 2023 | Volume: 11 | Issue: 6 | Pages: 763-776

10.1158/2326-6066.cir-22-0570 | PMID 36921098 Get It

Abstract Glioblastoma (GBM) is the most common malignant brain tumor in adults, responsible for approximately 225,000 deaths per year. Despite preclinical successes, most interventions have failed to extend patient survival by more than a few months. Treatment with anti—programmed cell death protein 1 (anti–PD-1) immune checkpoint blockade (ICB) monotherapy has been beneficial for malignant tumors such as melanoma and lung cancers but has yet to be effectively employed in GBM. This study aimed to determine whether supplementing anti–PD-1 ICB with engineered extended half-life IL2, a potent lymphoproliferative cytokine, could improve outcomes. This combination therapy, subsequently referred to as enhanced checkpoint blockade (ECB), delivered intraperitoneally, reliably cures approximately 50% of C57BL/6 mice bearing orthotopic GL261 gliomas and extends median survival of the treated cohort. In the CT2A model, characterized as being resistant to CBI, ECB caused a decrease in CT2A tumor volume in half of measured animals similar to what was observed in GL261-bearing mice, promoting a trending survival increase. ECB generates robust immunologic responses, features of which include secondary lymphoid organ enlargement and increased activation status of both CD4 and CD8 T cells. This immunity is durable, with long-term ECB survivors able to resist GL261 rechallenge. Through employment of depletion strategies, ECB's efficacy was shown to be independent of host MHC class I–restricted antigen presentation but reliant on CD4 T cells. These results demonstrate ECB is efficacious against the GL261 glioma model through an MHC class I–independent mechanism and supporting further investigation into IL2-supplemented ICB therapies for tumors of the central nervous system.
An Unusual Cause of GI Blood Loss
Travers, Paul , Pang, Maoyin , Travers, Paul M

Mayo Clinic

ACG Case Reports Journal | March 15, 2023 | Volume: 10 | Issue: 3 | Pages: e00992

10.14309/crj.0000000000000992 | PMID 36936130 Get It

ABSTRACT Chronic gastrointestinal bleeding is the leading cause of iron deficiency anemia in developed countries, and most occult bleeds are attributed to upper gastrointestinal tract lesions, which are broadly categorized into mass lesions, vascular, infectious, and inflammatory abnormalities. Gastric polyps account for an exceedingly small portion of these lesions but are of clinical importance because of the risk for progression to malignancy. We describe a patient found to have a gastric foveolar-type adenoma as a rare cause of iron deficiency anemia, with an incidentally found gastric neuroendocrine tumor.
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders
Nugent, Diane J. , Acharya, Suchitra S. , Baumann, Kimberly J., Bedrosian, Camille L. , Bialas, Rebecca, Brown, Kai , Corzo, Deya, Haidar, Amar, Hayward, Catherine P.M. , Miller, Margaret E., Nammacher, Kate, Peltier, Skye , Pruthi, Rajiv K. , Sørensen, Benny, Tarantino, Michael D. , Wolberg, Alisa S. , Menegatti, Marzia , Palla, Roberta , Peltier, Skye , Pruthi, Rajiv K , Recht, Michael , Wolberg, Alisa S , Shapiro, Amy D , Baumann, Kimberly, Corzo, Deyanira , Marks, Peter

Mayo Clinic

Expert Review of Hematology | March 15, 2023 | Volume: 16 | Issue: sup1 | Pages: 55-70

10.1080/17474086.2023.2175661 | PMID 36920862 Get It

A Community Paramedic Clinic at a Day Center for Adults Experiencing Homelessness
Ridgeway, Jennifer L. , Finnie, Dawn M., Wiepert, Liana M , Glasgow, Amy E. , Torres, Andrew J., Juntunen, Michael B. , Liedl, Chad P., Ridgeway, Jennifer L , Gerdes, Erin O. Wissler , Zhu, Xuan , Torres, Andrew J., Smith, Olivia A., McCoy, Rozalina G.

Mayo Clinic

NEJM Catalyst | March 15, 2023 | Volume: 4 | Issue: 4 | Pages: No page available

10.1056/cat.22.0300 Get It

An update on long‐term outcomes of pediatric follicular mucinosis over a 20‐year period: a retrospective cohort study
Jin, Mauricio F. , Ali, Nora S., Johnson, Emma F. , Gibson, Lawrence E. , Johnson, E F , Davis, Dawn Marie R.

Mayo Clinic

International Journal of Dermatology | March 15, 2023 | Volume: 62 | Issue: 8 | Pages: 1056-1059

10.1111/ijd.16639 | PMID 36919978 Get It

AbstractBackgroundFollicular mucinosis (FM) is a rare disease characterized by mucin accumulation in the follicular unit. FM's etiology is still widely debated since its first description in 1957. Follicular mucinosis is usually reported to be benign in children, although reports of malignant transformation, most commonly mycosis fungoides, exist. The present project aims to demonstrate that children with a diagnosis of follicular mucinosis have positive long‐term outcomes and do not develop mycosis fungoides.Materials and methodsThis is a retrospective cohort study where patients with a diagnosis of follicular mucinosis ages 22 years and below were identified. Data surrounding the patient's diagnosis of FM, differential diagnosis, treatments, and long‐term outcomes were collected. Patients who were lost to follow‐up were contacted by phone for an update on the status of their skin and overall health.ResultsOut of 14 patients with follow‐up information, none developed subsequent mycosis fungoides or other hematologic malignancies.ConclusionPediatric patients with follicular mucinosis will likely present with limited disease and not experience malignant transformation.
A novel APOA1 frameshift mutation Glu120Glyfs*60 with upper gastrointestinal involvement and an indolent course
Dasari, Surendra , Theis, Jason D. , Ongie, Laura , Cabral, Huong, Cabral, Huong T, Dispenzieri, Angela , Muchtar, Eli , Cabral, Huong, McPhail, Ellen Darcy , Dispenzieri, Angela , Gertz, Morie A. , Rech, Karen L.

Mayo Clinic

Amyloid | March 15, 2023 | Volume: 30 | Issue: 3 | Pages: 353-355

10.1080/13506129.2023.2187679 | PMID 36919584 Get It

Performance Comparisons of Methylation and Structural Variants From Low-Input Whole-Genome Methylation Sequencing
Sun, Zhifu , Behati, Saurabh, Wang, Panwen , Bhagwate, Aditya , McDonough, Samantha J., Wang, Vivian , Cunningham, Julie M. , McDonough, Samantha, Cunningham, Julie, Kisiel, John, Sun, Zhifu , Taylor, William R. , Kisiel, John B.

Mayo Clinic

Epigenomics | March 15, 2023 | Volume: 15 | Issue: 1 | Pages: 11-19

10.2217/epi-2022-0453 | PMID 36919677 Get It